Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Securities in F&O Ban:
Sammaan Capital and Steel Authority of India shares are banned from F&O trading on 13 April 2026.
Result Today:
ICICI Prudential Asset Management Company, Just Dial, Swaraj Engines, Innovision, Parin Enterprises, Indbank Housing and Continental Controls will announce their quarterly earnings today.
IPO Update:
Om Power reported 0.71x subscription on Day 2
Om Power’s initial public offering (IPO) was subscribed 0.71 times overall on Day 2 (as of 5:00 PM), with Qualified Institutional Buyers (QIBs) subscribing 1.18 times, the retail portion at 0.58 times, and Non-Institutional Investors (NIIs) at 0.38 times.
Stocks to Watch:
Panacea Biotec announced that it has received a letter of award (LoA) worth Rs 20.79 crore from Central Medical Services Society, under the Ministry of Health and Family Welfare, Government of India.
Advance Agrolife announced that it has received a letter of intent (LoI) worth Rs 30.37 crore from National Fertilizers for the supply of various agrochemicals.
Zaggle Prepaid Ocean Services announced that it has entered into an agreement with Generali Central Insurance Company (formerly known as Future Generali India Insurance Company Limited) to provide its Zaggle Zoyer platform.
Emerald Leisures said that it has received a letter of intent (LoI) for the development of a residential redevelopment project at Swastik Park, Chembur in Mumbai, with an estimated revenue potential of around Rs 600 crore.
Larsen & Toubro said its real estate arm, L&T Realty Properties, has acquired a 100% stake in International Green Scapes for Rs 1,123 crore in an all-cash deal, as it looks to expand its residential portfolio in Gurugram.
Airfloa Rail Technology said that it has secured a domestic order worth Rs 1.25 crore from Rail Coach Factory Kapurthala for the supply of luggage rack modules for LHB non-AC and AC chair car coaches.
Blue Dart Express reported a low-severity cyber security incident within its parent group. The company said the incident involved phishing and impersonation exposure. It clarified that no sensitive data was breached and no customer or business information was impacted.
Swiggy’s Co-founder Nandan Reddy has stepped down to pursue personal projects, while Chief Growth Officer Phani Kishan and Group CFO Rahul Bothra will join the board as Executive Directors.
Laxmi Organic announced that it has appointed Harshvardhan Goenka as Interim CFO following the resignation of Mahadeo Karnik.
LIC Housing Finance announced that it has appointed Sanjay Dayal as its Chief Operating Officer (COO).
The company clarified that the order has been awarded by a domestic entity and is in the nature of vaccine supply. It further stated that neither its promoters nor promoter group entities have any interest in the awarding authority, and the transaction does not fall under related-party transactions.
Panacea Biotec is a research-based biotechnology company engaged in the business of research, development, manufacture, and marketing vaccines in India and international markets.
The company reported a consolidated net loss of Rs 7.36 crore in Q3 FY26 as against a net profit of Rs 9.65 crore in Q3 FY25. Revenue from operations declined 8.4% year on year to Rs 99.31 crore in Q3 FY26.
Shares of Panacea Biotec rose 1.23% to end at Rs 326 on 10 April 2026.
Pharma shares tumbled for third straight session.
At 12:25 ST, the barometer index, the S&P BSE Sensex declined 308.73 points or 0.36% to 85,104.61. The Nifty 50 index dropped 79.30 points or 0.30% to 26,063.35.
The broader market outperformed the frontline indices. The S&P BSE Mid-Cap index rose 0.19% and the S&P BSE Small-Cap index added 0.04%.
The market breadth was negative. On the BSE, 1,848 shares rose and 2,140 shares fell. A total of 205 shares were unchanged.
Derivatives:
The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, fell 0.48% to 9.15. The Nifty 30 December 2025 futures were trading at 26,081.50, at a premium of 18.15 points as compared with the spot at 26,063.35.
The Nifty option chain for the 30 December 2025 expiry showed a maximum call OI of 285 lakh contracts at the 26,100 strike price. Maximum put OI of 196.4 lakh contracts was seen at 26,000 strike price.
Buzzing Index:
The Nifty Pharma index declined 0.39% to 22,668.10. The index declined 1.13% in the three consecutive trading sessions.
Sun Pharmaceutical Industries (down 1.66%), Piramal Pharma (down 1.29%), Ajanta Pharma (down 0.79%), Alkem Laboratories (down 0.75%), Ipca Laboratories (down 0.67%), Zydus Lifesciences (down 0.65%), Torrent Pharmaceuticals (down 0.61%), Mankind Pharma (down 0.53%), Glenmark Pharmaceuticals (down 0.5%) and Lupin (down 0.1%) declined.
Stocks in Spotlight:
NTPC rose 0.95%. The company announced the commercial operation of the remaining 13 MW of its 23 MW Solapur Solar PV Project in Maharashtra, taking the project to full capacity.
Apollo Micro Systems climbed 2.17% after the company received orders amounting to Rs 100.24 crore from a private company for the supply of Unmanned Aerial Systems.
Panacea Biotec surged 14.66% after it has received an award from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of its WHO pre-qualified pentavalent vaccine, Easyfive-TT, for 2023–2027.
Panacea Biotec Ltd, Hisar Metal Industries Ltd, Allcargo Terminals Ltd Partly Paidup and Rico Auto Industries Ltd are among the other gainers in the BSE's 'B' group today, 26 December 2025.
Prakash Steelage Ltd surged 20.00% to Rs 4.98 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 1.43 lakh shares were traded on the counter so far as against the average daily volumes of 30932 shares in the past one month.
Panacea Biotec Ltd soared 13.97% to Rs 408.6. The stock was the second biggest gainer in 'B' group. On the BSE, 11.94 lakh shares were traded on the counter so far as against the average daily volumes of 4604 shares in the past one month.
Hisar Metal Industries Ltd spiked 12.65% to Rs 187. The stock was the third biggest gainer in 'B' group. On the BSE, 6 shares were traded on the counter so far as against the average daily volumes of 632 shares in the past one month.
Allcargo Terminals Ltd Partly Paidup exploded 12.08% to Rs 12.9. The stock was the fourth biggest gainer in 'B' group. On the BSE, 1 shares were traded on the counter so far as against the average daily volumes of 9147 shares in the past one month.
Rico Auto Industries Ltd advanced 11.83% to Rs 140.35. The stock was the fifth biggest gainer in 'B' group. On the BSE, 13.34 lakh shares were traded on the counter so far as against the average daily volumes of 16.05 lakh shares in the past one month.
Under the revision, the contract value for 2026 has been increased by $2.55 million (around Rs 23 crore) to $16.8 million, while the 2027 allocation rises by $2.70 million (around Rs 24 crore) to $15.18 million. Additionally, an extra award for 2027 worth $3.68 million (about Rs 33 crore) has been included, taking the total incremental value to $8.93 million (roughly Rs 80 crore) for the two years.
The international supply contract will be executed as per orders received from UNICEF during CY2026 and CY2027. UNICEF is expected to publish details of the award, including supplier name, vaccine, duration, total value, and awarded prices per product on its official website.
Panacea Biotec said the award does not involve any promoter or promoter group interest.
Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture, and marketing of vaccines in India and international markets.
The company reported a consolidated net loss of Rs 13.92 crore in Q2 FY26 as against a net profit of Rs 4.80 crore in Q2 FY25. Revenue from operations declined 4.2% year on year to Rs 141.13 crore in Q2 FY25.
Shares of Panacea Biotec shed 0.67% to Rs 354.95 on the BSE.
The company will supply Easyfive TT vaccine during calendar year 2026 and 2027.
Panacea Biotec is a research-based biotechnology companies engaged in the business of research, development, manufacture and marketing of vaccines in India and international markets.
The company reported consolidated net profit of Rs 4.05 crore in Q1 FY26 as against net loss of Rs 15.80 crore in Q1 FY25. Revenue from operations jumped 44.1% year on year to Rs 166.70 crore in Q1 FY26.
The counter declined 2.24% to end at Rs 396.40 on Tuesday, 11 November 2025.